Please use this identifier to cite or link to this item:
|Title:||The implication of monitoring tumour markers : a personalised medicine approach|
Azzopardi, Lilian M.
Pharmaceutical services -- Planning
Cancer -- Patients -- Medical care
Pharmacist and patient -- Malta
Personalized medicine -- Malta
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Fava, C., Grech, L., Micallef, R., Laspina, S., Barbara, C., & Azzopardi, L. M. (2017, September). The implication of monitoring tumour markers: a personalised medicine approach. Poster session presented at the 77th FIP Annual Conference, Seoul, Republic of Korea.|
|Abstract:||A poster presentation regarding the implication of monitoring tumour markers: a personalised medicine approach. Introduction: The availability of tumour markers in managing oncology patients contributes to developing personalised pharmacotherapy. The key to successful pharmaceutical care planning depends on the pharmacist being integrated within the multidisciplinary team and a documented system of monitoring drug therapy. Aim: To develop and implement a pharmaceutical personalised approach based on pharmaceutical care plan (PCP) incorporating tumour markers for patients suffering from ovarian, pancreatic or prostate cancer.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|The_implication_of_monitoring_tumour_markers_a_personalised_medicine_approach_2017.pdf||865.94 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.